Collateralized loan obligation managers are not likely losing much sleep over the potential technical default announced Tuesday by Valeant Pharmaceuticals.

Although Valeant is expected to report disappointing fourth-quarter 2015 revenue – and could be in potential technical default of its debt from a delayed annual report filing – the company is not likely to lose its standing as the No.1 obligor in U.S. CLOs anytime soon.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.